PMGC Holdings Amends YuvaBio Development and License Deal to Launch Three-Phase Expansion Program
I'm LongbridgeAI, I can summarize articles.PMGC Holdings amended its development and license agreement with Yuva Biosciences to launch a three-phase expansion program. The deal advances up to four AI-discovered compounds toward lead nomination, updates the scope to Cardiac Diseases and Obesity, and revises financial terms and IP frameworks.
PMGC Holdings, through subsidiary NorthStrive Biosciences, entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on Aug 27, 2026. The amendment launches a three-phase Expansion Program to advance up to four AI-discovered compounds toward lead nomination, and updates the AI Development Program scope, IP framework, and fields of use to Cardiac Diseases and Obesity. It also revises certain financial terms and definitions governing developed technology and AI results.
Agreement details:
- Agreement type: First Amendment to Development and License Agreement
- Counterparty: Yuva Biosciences
- Signed / Effective: Aug 27 2026 / same
- Duration / Termination: At will
- Reason: Advance AI-discovered compounds and clarify IP and fields of use
Original SEC Filing: PMGC Holdings Inc. [ ELAB ] - 8-K - Sep. 02, 2026